NASDAQ: RARE
Ultragenyx Pharmaceutical Inc Stock Ownership - Who owns Ultragenyx Pharmaceutical?

Insider buying vs selling

Have Ultragenyx Pharmaceutical Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Howard HornChief Financial Officer2025-10-137,942$31.51
$250.25kSell
Theodore Alan HuizengaSVP Chief Accounting Officer2025-09-1864$29.17
$1.87kSell
Karah Herdman ParschauerEVP and Chief Legal Officer2025-09-122,450$31.17
$76.37kSell
Theodore Alan HuizengaSVP Chief Accounting Officer2025-09-0584$31.39
$2.64kSell
Corazon Corsee D. SandersDirector2025-06-202,405$37.39
$89.92kSell
Eric CrombezEVP and Chief Medical Officer2025-05-05520$39.24
$20.40kSell
Eric CrombezEVP and Chief Medical Officer2025-04-21242$35.11
$8.50kSell
Howard HornChief Financial Officer2025-03-061,785$40.40
$72.11kSell
Eric CrombezEVP and Chief Medical Officer2025-03-038,945$42.10
$376.58kSell
Erik HarrisEVP Chief Commercial Officer2025-03-0315,103$42.10
$635.84kSell

1 of 3

RARE insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RARE insiders and whales buy or sell their stock.

RARE Shareholders

What type of owners hold Ultragenyx Pharmaceutical Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Vanguard Group Inc10.50%10,132,728$339.14MInstitution
Emil D. Kakkis7.55%7,288,686$243.95MInsider
Fmr LLC7.55%7,283,296$243.77MInstitution
Blackrock Inc6.66%6,425,263$215.05MInstitution
Fmr LLC4.89%4,718,234$157.92MInsider
Jpmorgan Chase Co4.16%4,011,429$134.26MInstitution
Sands Capital Management LLC3.91%3,769,853$126.18MInstitution
State Street Corp3.83%3,692,487$123.59MInstitution
Rtw Investments LP3.38%3,258,266$109.05MInstitution
Baker Bros Advisors LP2.87%2,772,692$92.80MInstitution

1 of 3

RARE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RARE85.63%14.37%Net SellingNet Selling
IRON57.82%42.18%Net SellingNet Selling
TARS73.35%26.65%Net SellingNet Selling
CGON84.77%15.23%Net BuyingNet Buying
XENE97.13%2.87%Net BuyingNet Buying

Ultragenyx Pharmaceutical Stock Ownership FAQ

Who owns Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ: RARE) is owned by 98.96% institutional shareholders, 16.60% Ultragenyx Pharmaceutical insiders, and 0.00% retail investors. Emil D. Kakkis is the largest individual Ultragenyx Pharmaceutical shareholder, owning 7.29M shares representing 7.55% of the company. Emil D. Kakkis's Ultragenyx Pharmaceutical shares are currently valued at $265.67M.

If you're new to stock investing, here's how to buy Ultragenyx Pharmaceutical stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.